Posted by Michael Wonder on 13 May 2024
Boehringer Ingelheim expands access to adalimumab-adbm injection, the company's biosimilar to Humira
13 May 2024 - Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), in the US.
Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialise Boehringer Ingelheim-labeled Cyltezo (adalimumab-adbm) injection and adalimumab-adbm.
